Abstract:Abstract Genome editing represents a promising tool to manipulate human hematopoietic stem and progenitor cells (HSPCs) opening the possibility to correct hematopoietic diseases avoiding the risk of insertional mutagenesis and uncontrolled expression of the transgene, issues that emerged with retroviral and lentiviral gene therapy. Engineered nucleases such as CRISPR/Cas9 have enable targeted genetic manipulation in human HSPCs for therapeutic purposes. Still, nuclease-induced DNA double-strand breaks (DSBs) trigger p53-dependent DNA damage response affecting HSPC properties and may lead to unintended chromosomal rearrangements. Base editing (BE) holds the promise for precise editing by the introduction of specific single-nucleotide variants (SNVs) while bypassing the requirement for DSBs. In particular, base editors are composed by: i) a deamination domain that directly modifies nucleotides comprised within a defined editing window in one of the two genomic strands, and ii) a nickase Cas9 that introduces a single-strand break (SSB) on the other strand to promote more efficient base editing. Depending on the type of modification introduced editors are classified in Cytosine (C-) BE (C-G transition to T-A) and Adenine (A-) BE (A-T transition to G-C). However, a comprehensive characterization of efficiency, tolerability and genotoxicity of CBE and ABE in human HSPCs is lacking and is required to instruct the rationale towards safe and effective clinical translation. Here, we developed an optimized mRNA-based protocol for BE in human HSPCs and compared CBE4max, ABE8.20-m and Cas9 nuclease by targeting the same locus (B2M) using the same sgRNA. Common outcome for all editors is disruption of targeted gene expression, which is measured by flow cytometry and Next Generation Sequencing. ABE8.20-m showed higher efficiency than CBE4max and Cas9 nuclease at the target locus (up to 90, 40 and 50%), which was consistent across HSPC subpopulations comprising the most primitive compartment endowed with long term repopulation potential and cell sources (such as cord blood- and mobilized peripheral blood-derived HSPCs). Importantly, Cas9, but not CBE4max and ABE8.20m, treated HSPCs showed lower in-vitro clonogenic capacity than mock electroporated cells. Transcriptional analyses uncovered that CBE4max, but not ABE8.20-m, triggered p53 pathway activation, albeit at lower extent as compared to Cas9 and presumably consequent to a fraction of single-strand nicks turning into DSB upon DNA replication. Additionally, BE, and particularly CBE4max, upregulated the expression of interferon-stimulated genes, which was not ascribed to mRNA delivery. Remarkably, despite edited HSPCs showed long-term multilineage capacity in xenotransplanted mice, CBE4max edited cells tended to decrease over time in the graft pointing to some detrimental response to the treatment of the long-term engrafting HSC subset. Overall, our results prompt further investigation on BE sensing in human HSPCs. On-going studies are aimed to investigate clonal dynamics and genome integrity of base-edited HSPCs with the final goal of building confidence for their perspective clinical translation. Disclosures Naldini: Genenta Science: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees, Other: Founder.

Direct delivery of stabilized Cas-embedded base editors achieves efficient and accurate editing of clinically relevant targets

Direct delivery of Cas-embedded cytosine base editors as ribonucleoprotein complexes for efficient and accurate editing of clinically relevant targets

Two Compact Cas9 Ortholog-Based Cytosine Base Editors Expand the DNA Targeting Scope and Applications In Vitro and In Vivo

Efficient generation of site-specific point mutations in cell lines by hyper active CBEs (hyCBEs)

Eliminating Base-Editor-induced Genome-Wide and Transcriptome-Wide Off-Target Mutations

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Increasing the Efficiency and Targeting Range of Cytidine Base Editors Through Fusion of a Single-Stranded DNA-binding Protein Domain

Efficient C-to-G Base Editing with Improved Target Compatibility Using Engineered Deaminase-nCas9 Fusions.

Efficient DNA base editing via an optimized DYW-like deaminase

Re-engineering the adenine deaminase TadA-8e for efficient and specific CRISPR-based cytosine base editing

Precise base editing with CC context-specificity using engineered human APOBEC3G-nCas9 fusions

Efficient and High-Fidelity Base Editor with Expanded PAM Compatibility for Cytidine Dinucleotide

Engineering APOBEC3A deaminase for highly accurate and efficient base editing

Expanding the Genome-Targeting Scope and the Site Selectivity of High-Precision Base Editors

Glycosylase-based Base Editors for Efficient T-to-G and C-to-G Editing in Mammalian Cells

Assessing Stealth and Sensed Base Editing in Human Hematopoietic Stem/Progenitor Cells

Develop a Compact RNA Base Editor by Fusing ADAR with Engineered EcCas6e

Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors

Rational Design of Enhanced Nme2Cas9 and Nme2 Cas9 Nucleases and Base Editors

Accelerated discovery and miniaturization of novel single-stranded cytidine deaminases

nCas9 Engineering for Improved Target Interaction Presents an Effective Strategy to Enhance Base Editing